Tesamorelin or AOD 9604: How These Two Peptides Compare

Tesamorelin and AOD 9604 are both synthetic peptides studied for their effects on body fat, but they are not interchangeable. Tesamorelin is an FDA-approved growth hormone-releasing hormone (GHRH) analog, while AOD 9604 is an investigational fragment of human growth hormone that has never been approved for human use in the United States. The right choice depends on whether you need a prescription medicine with trial data or you are evaluating a research chemical.

This guide breaks down how the two peptides differ in approval status, mechanism, evidence, and safety so you can ask better questions of a clinician or read the primary literature with more context.

What Tesamorelin Is and What It Does

Tesamorelin is a stabilized form of GHRH, the hormone your hypothalamus uses to signal growth hormone release from the pituitary gland. It is sold in the US as Egrifta WR and is FDA-approved for one narrow indication: reducing excess visceral abdominal fat in adults living with HIV-associated lipodystrophy.

In randomized controlled trials, daily subcutaneous tesamorelin reduced visceral adipose tissue and improved some lipid measurements in that population. Those studies did not enroll healthy adults seeking cosmetic fat loss, so the results should not be generalized to everyone.

Key facts about tesamorelin:

• Approval status: FDA-approved, prescription only.
• Class: GHRH analog.
• Approved use: HIV-associated lipodystrophy, not general weight loss.
• Approved dose: 2 mg injected subcutaneously once daily.
• Human evidence: multiple randomized controlled trials.
• Common side effects: injection-site reactions, joint pain, muscle pain, swelling, and elevated IGF-1.

What AOD 9604 Is and What It Does

AOD 9604 is a peptide fragment that matches the 176-191 region of human growth hormone. Scientists designed it to copy the fat-metabolizing portion of HGH while avoiding its effects on growth and blood sugar.

AOD 9604 was studied as an anti-obesity candidate in the 2000s, including Phase II trials, but it never received FDA approval. Today it is sold primarily as a research chemical, often with a "not for human consumption" label.

Key facts about AOD 9604:

• Approval status: not FDA-approved for any human use.
• Class: HGH fragment 176-191.
• Studied effect: fat metabolism and lipolysis.
• Human evidence: limited, older trials with mixed results.
• Reported side effects: headache, nausea, and injection-site irritation in small studies.
• Legal status: not a controlled substance, but not legal to sell as a drug or dietary supplement.

How Tesamorelin and AOD 9604 Compare

Most searches for aod 9604 vs tesamorelin come from people trying to decide between an approved prescription drug and an unapproved research peptide. The table below summarizes the main differences.

The tesamorelin vs aod 9604 comparison is uneven in one important way: human evidence. Tesamorelin has been tested in large, controlled trials for a defined medical condition, while AOD 9604 has small studies and no regulatory review.

Stacking AOD 9604 With Tesamorelin

Some online communities discuss using aod 9604 with tesamorelin in the same protocol, hoping to combine two pathways that affect fat storage. No published clinical trial has tested that combination in humans.

A related trend is the aod-9604 mots-c tesamorelin stack, which adds MOTS-c, a mitochondrial-derived peptide, to the mix. MOTS-c is also investigational and not approved for human use. Stacking multiple unapproved peptides multiplies unknowns without adding proven benefit.

Overlapping side effects are a real concern. Tesamorelin can raise IGF-1 and cause joint pain or fluid retention, and adding unapproved peptides makes it harder to identify what is causing a reaction. There is also no reliable way to verify the purity or identity of most research chemical products.

Safety, Legality, and What to Ask a Clinician

The safety profiles of these two peptides are not comparable.

• Tesamorelin is a prescription drug, so a clinician can monitor IGF-1, blood sugar, and injection-site reactions.
• AOD 9604 has no established human dose and no post-market safety data.
• Peptides sold online may be mislabeled, underdosed, or contaminated.
• Neither peptide replaces nutrition, exercise, or medical care, and fat loss from any single peptide tends to be modest.

AOD 9604 is not FDA-approved for human use in the United States, and buying it from a vendor carries legal and health risks. Tesamorelin is legal only with a prescription for its approved indication. Tell your healthcare provider about every peptide you are considering, including anything purchased online.

Bottom Line

Tesamorelin and AOD 9604 are different molecules with very different evidence levels. Tesamorelin has FDA approval for a narrow indication and strong trial data within that group. AOD 9604 remains an investigational fragment with no approved human use and inconsistent data.

Anyone weighing aod 9604 peptide vs tesamorelin for general fat loss should know that neither peptide is approved for cosmetic weight loss. The decision belongs with a licensed clinician who knows your history, not with a vendor or a forum post.

Researchers should rely on primary literature rather than dosage charts circulating on social media. Patients should ask about approved options first, then discuss risks, benefits, and monitoring for anything else.